Literature DB >> 24392780

Immunization with hybrid proteins containing the membrane proximal external region of HIV-1.

Nicola Strasz1, Vladimir A Morozov, Jürgen Kreutzberger, Martina Keller, Magdalena Eschricht, Joachim Denner.   

Abstract

The transmembrane envelope (TM) protein gp41 of HIV-1 is an attractive target when designing a vaccine to induce neutralizing antibodies. A few broadly neutralizing antibodies (2F5, 4E10, and 10E8) that target conserved epitopes in the membrane proximal external region (MPER) of gp41 have been isolated from infected individuals. However, attempts to induce such antibodies by immunizations with gp41 and Env derivatives containing the MPER were successful only to some extent. In contrast, immunizations with the ectodomain of the TM protein p15E of different gamma retroviruses resulted in the induction of neutralizing antibodies. These sera recognized epitopes located in the MPER and in the fusion peptide proximal region (FPPR) of p15E. Based on these results, both regions of p15E were substituted with the corresponding sequences derived from gp41 of HIV-1. Thus, four different hybrid antigens were produced. One of the inserted sequences contained the epitopes of 2F5 and 4E10 in the MPER; the other corresponded to the FPPR. Vaccination of rats, guinea pigs, and a goat induced binding antibodies directed against the FPPR of gp41 and the 2F5 epitope (ELDKWA) located in the MPER. Despite the exact recognition of the 2F5 epitope, no or very weak neutralization of HIV-1NL4-3 by the immune sera was demonstrated. Nonetheless, using the strategy of hybrid proteins, antibodies targeting the desired epitope were successfully induced.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24392780      PMCID: PMC4010167          DOI: 10.1089/AID.2013.0191

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  46 in total

1.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  The HIV-neutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen.

Authors:  Christine Hager-Braun; Hermann Katinger; Kenneth B Tomer
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

4.  A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library.

Authors:  K Büssow; D Cahill; W Nietfeld; D Bancroft; E Scherzinger; H Lehrach; G Walter
Journal:  Nucleic Acids Res       Date:  1998-11-01       Impact factor: 16.971

Review 5.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

6.  Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI.

Authors:  C Petrovas; P G Vlachoyiannopoulos; T Kordossis; H M Moutsopoulos
Journal:  J Autoimmun       Date:  1999-11       Impact factor: 7.094

7.  Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation?

Authors:  Uwe Fiebig; Oliver Stephan; Reinhard Kurth; Joachim Denner
Journal:  Virology       Date:  2003-03-15       Impact factor: 3.616

8.  Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.

Authors:  Erin M Scherer; Michael B Zwick; Luc Teyton; Dennis R Burton
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

9.  Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.

Authors:  Flavia Ferrantelli; Robert A Rasmussen; Kathleen A Buckley; Pei-Lin Li; Tao Wang; David C Montefiori; Hermann Katinger; Gabriela Stiegler; Daniel C Anderson; Harold M McClure; Ruth M Ruprecht
Journal:  J Infect Dis       Date:  2004-05-26       Impact factor: 5.226

10.  Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion.

Authors:  Anna K Bellamy-McIntyre; Chan-Sien Lay; Séverine Baär; Anne L Maerz; Gert H Talbo; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2007-05-25       Impact factor: 5.157

View more
  9 in total

1.  Molecular and Physicochemical Factors Governing Solubility of the HIV gp41 Ectodomain.

Authors:  Fadia Manssour-Triedo; Sara Crespillo; Bertrand Morel; Salvador Casares; Pedro L Mateo; Frank Notka; Marie G Roger; Nicolas Mouz; Raphaelle El-Habib; Francisco Conejero-Lara
Journal:  Biophys J       Date:  2016-08-23       Impact factor: 4.033

2.  A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.

Authors:  Rachel P J Lai; Miriam Hock; Jens Radzimanowski; Paul Tonks; David Lutje Hulsik; Gregory Effantin; David J Seilly; Hanna Dreja; Alexander Kliche; Ralf Wagner; Susan W Barnett; Nancy Tumba; Lynn Morris; Celia C LaBranche; David C Montefiori; Michael S Seaman; Jonathan L Heeney; Winfried Weissenhorn
Journal:  J Biol Chem       Date:  2014-08-26       Impact factor: 5.157

3.  Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.

Authors:  Habtom H Habte; Saikat Banerjee; Heliang Shi; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2015-10-09       Impact factor: 3.616

4.  Induction of neutralizing antibodies specific for the envelope proteins of the koala retrovirus by immunization with recombinant proteins or with DNA.

Authors:  Uwe Fiebig; Britta Dieckhoff; Christian Wurzbacher; Annekathrin Möller; Reinhard Kurth; Joachim Denner
Journal:  Virol J       Date:  2015-04-30       Impact factor: 4.099

5.  Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals.

Authors:  Luis M Molinos-Albert; Jorge Carrillo; Marta Curriu; Maria L Rodriguez de la Concepción; Silvia Marfil; Elisabet García; Bonaventura Clotet; Julià Blanco
Journal:  Retrovirology       Date:  2014-06-07       Impact factor: 4.602

6.  DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity.

Authors:  Lara Ajamian; Luca Melnychuk; Patrick Jean-Pierre; Gerasimos J Zaharatos
Journal:  Viruses       Date:  2018-02-27       Impact factor: 5.048

Review 7.  The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.

Authors:  Huan Liu; Xiaojie Su; Lulu Si; Lu Lu; Shibo Jiang
Journal:  Protein Cell       Date:  2018-04-17       Impact factor: 14.870

Review 8.  Neutralizing Antibodies Targeting HIV-1 gp41.

Authors:  Christophe Caillat; Delphine Guilligay; Guidenn Sulbaran; Winfried Weissenhorn
Journal:  Viruses       Date:  2020-10-23       Impact factor: 5.048

9.  The TZM-bl Reporter Cell Line Expresses Kynureninase That Can Neutralize 2F5-like Antibodies in the HIV-1 Neutralization Assay.

Authors:  Vladimir Morozov; Sylvie Lagaye; Alexey Morozov
Journal:  Int J Mol Sci       Date:  2022-01-07       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.